Myovant Sciences' Relugolix Combo Tablet For Uterine Fibroids Scores EMA Backing For Approval
- European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix, estradiol, and norethindrone acetate) for uterine fibroids.
- The final decision on the application is expected to be available in approximately two months.
- Gedeon Richter will commercialize Ryeqo for uterine fibroids, if approved, in Europe under an agreement announced in March 2020.
- Relugolix combination tablet for uterine fibroids is also under review by the FDA with a target action date of June 1.
- Price Action: MYOV shares are up 2.56% at $22.81 during the market session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Health Care FDA Movers Trading Ideas General
